16 recruiting, 8 active not recruiting, 8 completed, 4 not yet recruiting. 17 Phase 2, 14 Phase 1, 6 Phase 3, 5 Not applicable, 1 Early Phase 1.
Follow Locally Advanced Pancreatic Adenocarcinoma: new trials by email Literature Review of Locally Advanced Pancreatic Adenocarcinoma trials Research Report on Locally Advanced Pancreatic Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer Biospecimen Collection, Copper Cu 64-DOTA-A2DM, Positron Emission Tomography - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 15 | 2026-12-16 | 2026-05-27 |
| AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer Biopsy Procedure, Cisplatin, Computed Tomography - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Cholangiocarcinoma | Phase 1 | Recruiting | Jonsson Comprehensive Cancer Center | 46 | 2026-05-29 | 2026-08-20 |
| Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations Biospecimen Collection, Computed Tomography, Fluorouracil - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 94 | 2026-05-13 | 2026-05-22 |
| Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil - Metastatic Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma | Phase 2 | Recruiting | Medical University of South Carolina | 52 | 2026-04-02 | 2026-05-06 |
| A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer. XER-001 - Locally Advanced Pancreatic Adenocarcinoma, Locally Advanced Pancreas Cancer | Phase 1 / Phase 2 | Recruiting | Xerient Pharma | 36 | 2026-01-01 | 2026-08-17 |
| The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer Kinisoquin™, Placebo - Venous Thromboembolism, Metastatic Pancreatic Cancer | Phase 3 | Recruiting | Quercis Pharma AG | 480 | 2025-12-19 | 2026-02-02 |
| Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers standard radiotherapy with chemotherapy, MRI-guided adaptive stereotactic radiotherapy (SMART) - Locally Advanced Pancreatic Adenocarcinoma | Phase 2 | Not yet recruiting | Institut du Cancer de Montpellier - Val d'Aurelle | 160 | 2025-09-01 | 2025-07-31 |
| Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma RR001 - Locally Advanced Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | EIR Biotherapies s.r.l. | 9 | 2025-06-25 | 2026-09-08 |
| Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer Acoustic Cluster Therapy, Modified FOLFIRINOX - Locally Advanced Pancreatic Adenocarcinoma | Phase 2 | Recruiting | EXACT Therapeutics AS | 25 | 2025-06-19 | 2026-10-13 |
| PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) PTM-101 - Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma | Phase 1 | Recruiting | PanTher Therapeutics | 26 | 2025-04-14 | 2026-10-08 |
| A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment High dose radiation therapy - Locally Advanced Pancreatic Adenocarcinoma | Phase 2 | Recruiting | University Health Network, Toronto | 43 | 2025-03-12 | 2026-04-16 |
| Surgery for Locally Unresectable Pancreatic Cancer Questionnaire - Locally Advanced Pancreatic Adenocarcinoma | Recruiting | Azienda Ospedaliera di Padova | 150 | 2025-01-01 | 2025-11-26 | |
| Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer Biopsy, Biospecimen Collection, Computed Tomography - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 2 | Active not recruiting | Mayo Clinic | 24 | 2024-12-06 | 2026-06-18 |
| OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy OncoSil - Locally Advanced Pancreatic Adenocarcinoma | Not yet recruiting | OncoSil Medical Limited | 50 | 2024-05-30 | 2024-05-03 | |
| Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy MR guided radiotherapy - Locally Advanced Pancreatic Adenocarcinoma | Not applicable | Not yet recruiting | UMC Utrecht | 150 | 2024-02-01 | 2024-02-22 |
| PROACTIVE: Surgical Resection Outcomes in Locally Advanced and Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy Biospecimen Collection, Computed Tomography, Distal Pancreatectomy - Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer American Joint Committee on Cancer v8 | Not applicable | Active not recruiting | University of Southern California | 2 | 2023-12-01 | 2025-11-25 |
| Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC FOLFIRINOX or gemcitabine-nab-paclitaxel - Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Carcinoma | Phase 3 | Recruiting | Sahlgrenska University Hospital | 432 | 2023-10-18 | 2024-12-03 |
| Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer Stereotactic Ablative Body Radiation (SABR), Tumor Treating Fields (TTF) - Pancreas Cancer, Locally Advanced | Not applicable | Recruiting | Baptist Health South Florida | 48 | 2023-09-21 | 2026-01-12 |
| Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Nab paclitaxel, Gemcitabine, Radiological Assessments - Pancreas Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma | Phase 2 | Recruiting | Wake Forest University Health Sciences | 64 | 2023-08-01 | 2026-09-28 |
| Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma SD-101, anti-PD-1 - Locally Advanced Pancreatic Adenocarcinoma | Phase 1 | Active not recruiting | TriSalus Life Sciences, Inc. | 60 | 2023-03-01 | 2025-07-04 |
Showing 20 of 43. Sign in to see all of them.
Pancreatic Neoplasms (22) · Neoplasms (3) · Adenocarcinoma (2) · Pancreatic Diseases (2) · Anemia (1) · Blast Crisis (1) · Breast Neoplasms (1) · Carcinoma, Pancreatic Ductal (1) · Cholangiocarcinoma (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Hypoxia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1)
Neoplasms (23) · Endocrine Gland Neoplasms (22) · Endocrine System Diseases (22) · Neoplasms by Site (22) · Digestive System Diseases (21) · Digestive System Neoplasms (21) · Pancreatic Diseases (20) · Neoplasms by Histologic Type (5) · Carcinoma (4) · Neoplasms, Glandular and Epithelial (4) · Adenocarcinoma (2) · Cardiovascular Diseases (2) · Pathological Conditions, Signs and Symptoms (2) · Vascular Diseases (2) · Blood Platelet Disorders (1)
Gemcitabine (12) · Taxes (8) · Specimen Handling (7) · Fluorouracil (6) · Leucovorin (6) · Magnetic Resonance Spectroscopy (6) · Biopsy (5) · 130-nm albumin-bound paclitaxel (4) · Cisplatin (4) · Oxaliplatin (4) · dehydroftorafur (4) · Albumin-Bound Paclitaxel (3) · Irinotecan (3) · 1,2-diaminocyclohexaneplatinum II citrate (2) · Capecitabine (2)
National Cancer Institute (NCI) (3) · Institut du Cancer de Montpellier - Val d'Aurelle (2) · OHSU Knight Cancer Institute (2) · University Health Network, Toronto (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Azienda Ospedaliera di Padova (1) · Baptist Health South Florida (1) · City of Hope Medical Center (1) · EIR Biotherapies s.r.l. (1) · EXACT Therapeutics AS (1) · Fuda Cancer Hospital, Guangzhou (1) · Fudan University (1) · HonorHealth Research Institute (1) · Jonsson Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1)
United States (25) · Canada (3) · China (3) · Italy (3) · France (2) · Netherlands (2) · Sweden (2) · Australia (1) · Denmark (1) · Germany (1) · Israel (1) · Japan (1) · Norway (1) · United Kingdom (1)
A. M.E. Bruynzeel, MD, PhD (1) · Albert Lockhart, MD (1) · Charles D Lopez (1) · David Sher, MD (1) · Eileen M O'Reilly (1) · Elena Rangelova, PhD (1) · Elizabeth A Poplin (1) · Erica Tsang, MD (1) · Erkut Borazanci, MD (1) · Eugene J Koay, MD,PHD (1) · H. D. Heerkens, MD, PhD (1) · H. M.U. Peulen, MD, PhD (1) · J. J. Bosch (1) · Jeffrey Y Wong, MD (1)
PMID 27532020, PMID 29223478, PMID 35863672, PMID 37782888, PMID 38126766, PMID 38155512, PMID 38957079, PMID 39863139, PMID 39970867, PMID 39972248, PMID 40272619, PMID 42263216, PMID 42329186
N01CM00032 (1), N01CM00071 (1), P01CA084203 (1), P30CA008748 (1), P30CA012197 (1), P30CA014089 (1), P30CA033572 (1), P30CA072720 (1), R01CA266665 (1), U01CA069856 (1), U01CA132194 (1), U10CA180888 (1), UM1CA186691 (1), UM1CA186705 (1), UM1CA186716 (1)